Skip to Content
Merck
CN

5.00671

Sigma-Aldrich

HDAC Inhibitor XVII

Synonym(s):

HDAC Inhibitor XVII, (E)-N-Hydroxy-4-methoxy-2-(biphenyl-4-yl)cinnamide, Histone Deacetylase Inhibitor XVII

Sign Into View Organizational & Contract Pricing

Select a Size


About This Item

Empirical Formula (Hill Notation):
C22H19NO3
CAS Number:
Molecular Weight:
345.39
UNSPSC Code:
12352200
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Assay

≥99% (HPLC)

Quality Level

form

powder

potency

27 nM IC50

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

light beige

solubility

DMSO: 100 mg/mL

storage temp.

2-8°C

General description

A cell-permeable N-hydroxycinnamide derivative that acts a highly potent and HDAC8-selective histone deacetylase inhibitor (IC50 = 27 nM), displaying much reduced potency against HDAC1/3 (IC50 = 3.0 µM) and little or no activity toward HDAC2/4/6/10/11 (IC50 >20 µM) or total HDAC activity in HeLa nuclear extract (IC50 >10 µM). Reported to exhibit antiproliferative activity toward human lung cancer cells CL1-5, H1299, and A549 (IC50 = 7.0, 7.2, and 7.9 µM, respectively), while being much less toxic to low HDAC8-expressing CL1-1 (IC50 >10 µM) or normal human lung IMR-90 (73% inhibition at 40 µM) cells.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
HDAC8 selective
Reversible: yes

Packaging

Packaged under inert gas

Preparation Note

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Huang, W. J., et al. 2012. ChemMedChem.7, 1815.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Disclaimer

Toxicity: Standard Handling (A)

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Related Content

Cancer is a complex disease manifestation. At its core, it remains a disease of abnormal cellular proliferation and inappropriate gene expression. In the early days, carcinogenesis was viewed simply as resulting from a collection of genetic mutations that altered the gene expression of key oncogenic genes or tumor suppressor genes leading to uncontrolled growth and disease (Virani, S et al 2012). Today, however, research is showing that carcinogenesis results from the successive accumulation of heritable genetic and epigenetic changes. Moreover, the success in how we predict, treat and overcome cancer will likely involve not only understanding the consequences of direct genetic changes that can cause cancer, but also how the epigenetic and environmental changes cause cancer (Johnson C et al 2015; Waldmann T et al 2013). Epigenetics is the study of heritable gene expression as it relates to changes in DNA structure that are not tied to changes in DNA sequence but, instead, are tied to how the nucleic acid material is read or processed via the myriad of protein-protein, protein-nucleic acid, and nucleic acid-nucleic acid interactions that ultimately manifest themselves into a specific expression phenotype (Ngai SC et al 2012, Johnson C et al 2015). This review will discuss some of the principal aspects of epigenetic research and how they relate to our current understanding of carcinogenesis. Because epigenetics affects phenotype and changes in epigenetics are thought to be key to environmental adaptability and thus may in fact be reversed or manipulated, understanding the integration of experimental and epidemiologic science surrounding cancer and its many manifestations should lead to more effective cancer prognostics as well as treatments (Virani S et al 2012).

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service